Drug Type Biosimilar, Monoclonal antibody |
Synonyms Adalimumab Biosimilar (Wincal Biopharm Inc.), Adalimumab Eye Drop (Wincal Biopharm), 阿达木单抗滴眼液 (Wincal Biopharm) + [1] |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Uveitis | Preclinical | United States | 21 May 2023 |






